Neurobiology of Opioid Dependence: 5 - 5

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Yale University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000196

Purpose

The purpose of this study is to determine the effect of acute naltrexone pretreatment on the response to yohimbine in healthy volunteers.

Condition	Intervention	Phase
Opioid-Related Disorders	Drug: Naltrexone	Phase II

Study Type:	Interventional
Study Design:	Treatment, Double-Blind, Placebo Control
Official Title:	Neurobiology of Opioid Dependence: 5

Resource links provided by NLM:

Drug Information available for: Naltrexone Naltrexone hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Behavioral, physiological, neuroendocrine response to yohimbine

Estimated Enrollment:

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000196

Locations

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Yale University

Investigators

Principal Investigator:

Marc I Rosen, M.D.

VA Connecticut Healthcare System

More Information

No publications provided

Study ID Numbers:	NIDA-00191-5, K20-00191-5
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000196 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Sensory System Agents
Mental Disorders
Therapeutic Uses
Physiological Effects of Drugs
Narcotic Antagonists
Naltrexone

Substance-Related Disorders
Disorders of Environmental Origin
Peripheral Nervous System Agents
Opioid-Related Disorders
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 27, 2009